首页> 中文期刊> 《中国实用医药》 >立普妥对原发性高血压患者正常血脂和颈动脉内膜中层厚度的影响

立普妥对原发性高血压患者正常血脂和颈动脉内膜中层厚度的影响

         

摘要

目的:探讨阿托伐他汀钙(立普妥)10 mg/d对无动脉硬化原发性高血压患者正常血脂和颈动脉内膜中层厚度(CaIMT)的影响。方法102例血脂正常且无动脉硬化的原发性高血压患者,随机分为观察组52例,对照组50例,两组在常规降压治疗的基础上,观察组加用立普妥10 mg/d,分别于治疗前、治疗后6个月测定两组血脂、血压、CaIMT,比较两组变化差异。结果与治疗前比较,观察组治疗后6个月总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平显著下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)水平显著升高(P<0.05),对照组治疗前后血脂无明显变化(P>0.05)。两组患者血压均较基础值降低,与对照组相比观察组降低程度更为明显(P<0.05)。观察组CaIMT较治疗前及对照组均有显著降低(P<0.05),对照组CaIMT治疗前后改变不明显(P>0.05)。结论立普妥10 mg/d治疗无动脉硬化原发性高血压患者能显著改善血脂、降低血压、降低CaIMT,能有效预防原发性高血压患者发生动脉硬化。%Objective To explore the influence of 10 mg/d of atorvastatin calcium (Lipitor) on essential hypertension without arteriosclerosis patients’ normal blood lipid and carotid intima-media thickness (CaIMT). Methods A total of 102 cases of essential hypertension with normal blood lipid and without arteriosclerosis were randomly divided into observation group with 52 cases and control group with 50 cases. On the basis of conventional antihypertensive therapy, the observation group received 10 mg/d of Lipitor. Blood lipid, blood pressure and CaIMT were detected before and in 6 months after treatment. The differences of the two groups were compared.Results Compared with the indexes before treatment, the levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in 6 months after treatment of the observation group was decreased (P<0.05), and level of high-density lipoproteincholesterol (HDL-C) was increased (P<0.05). There was no significant difference in the control group before and after treatment (P>0.05). Blood pressure in both groups were lower than the basic value, and the decrease in observation group was more obvious than the control group (P<0.05). The level of CaIMT of the observation group was obviously decreased, compared with the control group and that before treatment (P<0.05). There was no significant difference of CaIMT in the control group before and after treatment (P>0.05).Conclusion 10 mg/d of Lipitor in the treatment of essential hypertension without arteriosclerosis can improve blood lipid, and decrease blood pressure and CaIMT, and it is an effective prevention of arteriosclerosis in essential hypertension.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号